Rapport Therapeutics reported a net loss of $24.06 million for the first quarter ended March 31, 2025, compared to a net loss of $22.67 million for the same period in the prior year. Basic and diluted loss per share from continuing operations stood at $0.68 for Q1 2025, a notable decrease from $11.07 per share reported in the first quarter of the previous year.
The company confirmed that enrollment in its Phase 2a trial for RAP-219 in patients with refractory focal epilepsy is progressing as planned. Topline data from this trial is expected in mid-2025, representing a significant upcoming catalyst for the company.
Rapport also highlighted that recent PET and MAD-2 trial results further validate the neuroanatomical specificity of TARPγ8 and the favorable tolerability profile of RAP-219. The company continues to advance its pipeline-in-a-product strategy, with the initiation of its bipolar mania trial progressing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.